Business Context and Reporting Period
This Form 8-K Current Report covers the period ending June 30, 2006, for Nephros, Inc., a Delaware corporation. The filing primarily reports the entry into a material definitive agreement involving the issuance of debt securities to raise capital.
Key Financial Metrics and Transaction Details
The filing details a specific financing transaction rather than providing comprehensive period-end financial statements (revenue, profit, or cash flow).
- Debt Issuance: Nephros sold an aggregate of $200,000 principal amount of 6% Secured Convertible Notes due 2012 to Kudu Partners, L.P. and LJHS Company.
- Interest Rate: 6% per annum, compounded annually, payable in arrears at maturity.
- Conversion Terms: Notes are convertible into common stock at an initial price of $2.10 per share.
- Security: The Notes are secured by substantially all of Nephros's assets.
- Total Financing Context: This transaction is a continuation of a financing round that began on June 1, 2006, with a prior sale of $5,000,000 in similar Notes.
Material Changes and Obligations
The primary material change is the creation of a direct financial obligation and the potential dilution of existing shareholders.
- Prepayment Warrants: If Nephros prepays the Notes on or before June 1, 2008, it must issue warrants to purchase common stock at $0.01 per share (3 shares for every $20 principal prepaid).
- Events of Default: The Notes may become immediately due upon failure to pay, bankruptcy events, material breach of representations, incurrence of Senior Debt, or acceleration of other debt.
- Registration Rights: Investors received demand and piggy-back registration rights for shares issuable upon conversion or warrant exercise.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, revenue outlook, or management commentary on operational performance.
- Regulatory Contingency: Nephros cannot issue shares upon conversion or warrant exercise until stockholders approve the issuance as required by American Stock Exchange rules.
- Forced Conversion: Nephros may force conversion if the common stock trades at an average last sales price of at least 240% of the conversion price with sufficient daily volume.
- Exemption Status: The securities were sold unregistered under Section 4(2) of the Securities Act and Regulation D.
Investor Verification Checklist
- Verify the total outstanding principal of the 6% Secured Convertible Notes (including the prior $5,000,000 issuance).
- Confirm the status of stockholder approval required by the American Stock Exchange for share issuance upon conversion.
- Assess the impact of potential prepayment warrants (exercise price $0.01) on future equity dilution.
- Review the definition of "Senior Debt" in the Note agreement to understand covenants restricting future borrowing.
- Check for any subsequent filings regarding the actual issuance of shares or warrants.